Jon E. Angell

Array ( [id] => 20108205 [patent_doc_number] => 12358911 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Heterocyclic comipound as CDK-HDAC dual pathway inhibitor [patent_app_type] => utility [patent_app_number] => 17/311627 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9996 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368199 [patent_doc_number] => 20220023251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA [patent_app_type] => utility [patent_app_number] => 17/311245 [patent_app_country] => US [patent_app_date] => 2019-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399487 [patent_doc_number] => 20220041577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Heterocyclic Compound as CDK-HDAC Double-Channel Inhibitor [patent_app_type] => utility [patent_app_number] => 17/309494 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 785 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383852 [patent_doc_number] => 20220031704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/297369 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290896 [patent_doc_number] => 20210386735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => Methods of Treating Acute HCV [patent_app_type] => utility [patent_app_number] => 17/295181 [patent_app_country] => US [patent_app_date] => 2019-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272817 [patent_doc_number] => 20210379015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => FEED ADDITIVE FOR CATTLE COMPRISING N-ACETYL-L-TRYPTOPHAN AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/287356 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8622 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334527 [patent_doc_number] => 20220000858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER [patent_app_type] => utility [patent_app_number] => 17/289913 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299415 [patent_doc_number] => 20210395254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => NEW TETRAHYDROPYRIMIDODIAZEPIN AND TETRAHYDROPYRIDODIAZEPIN COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/289761 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19373910 [patent_doc_number] => 12065459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-20 [patent_title] => Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders [patent_app_type] => utility [patent_app_number] => 16/672114 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30293 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 900 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16672114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334545 [patent_doc_number] => 20220000876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => DRUG COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/290150 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212519 [patent_doc_number] => 12409153 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Liquid injectable composition [patent_app_type] => utility [patent_app_number] => 17/289008 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 6054 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334541 [patent_doc_number] => 20220000872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => METHOD OF ENHANCING IMMUNE-BASED THERAPY [patent_app_type] => utility [patent_app_number] => 17/289963 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297749 [patent_doc_number] => 20210393588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => READY TO USE INTRAVENOUS INFUSION OF BRIVARACETAM OR SALT THEREOF [patent_app_type] => utility [patent_app_number] => 17/289786 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227077 [patent_doc_number] => 20210353633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/288721 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264093 [patent_doc_number] => 12435068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Anthelmintic compounds [patent_app_type] => utility [patent_app_number] => 17/287548 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41537 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 2314 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624052 [patent_doc_number] => 12162856 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => b-catenin and B-cell lymphoma 9 (BCL9) inhibitors [patent_app_type] => utility [patent_app_number] => 17/286693 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 26312 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 211 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411701 [patent_doc_number] => 12077506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Indane derivatives as hypoxia inducible factor-2(a) inhibitors [patent_app_type] => utility [patent_app_number] => 17/286818 [patent_app_country] => US [patent_app_date] => 2019-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25169 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299347 [patent_doc_number] => 20210395186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid [patent_app_type] => utility [patent_app_number] => 17/285653 [patent_app_country] => US [patent_app_date] => 2019-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274323 [patent_doc_number] => 20210380521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/284022 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20438609 [patent_doc_number] => 12509436 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Benzamide derivatives as cGAS-sting pathway agonists [patent_app_type] => utility [patent_app_number] => 17/282233 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18407 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282233 [rel_patent_id] =>[rel_patent_doc_number] =>)